|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR1900025539 |
|
最近更新日期: Date of Last Refreshed on: |
2019-08-31 22:21:10 |
|
注册时间: Date of Registration: |
2019-08-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
HBVDNA高载量孕期抗病毒宫内阻断产妇不同喂养方式母婴传播风险临床观察研究 |
|
Public title: |
The risk of different maternal feeding patterns in patients who had High HBVDNA load and received antiviral treatment during pregnancy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
HBVDNA高载量孕期抗病毒宫内阻断产妇不同喂养方式母婴传播风险临床观察研究 |
|
Scientific title: |
The risk of different maternal feeding patterns in patients who had High HBVDNA load and received antiviral treatment during pregnancy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
田瑞华 |
研究负责人: |
田瑞华 |
|
Applicant: |
Ruihua Tian |
Study leader: |
Ruihua Tian |
|
申请注册联系人电话: Applicant telephone: |
+86 13661060631 |
研究负责人电话: Study leader's telephone: |
+86 13661060631 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1572805079@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1572805079@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区右安门外西头条8号 |
研究负责人通讯地址: |
北京市丰台区右安门外西头条8号 |
|
Applicant address: |
8 Xitoutiao, You'anmenwai, Fengtai District, Beijing |
Study leader's address: |
8 Xitoutiao, You'anmenwai, Fengtai District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
首都医科大学附属北京佑安医院 |
||
|
Applicant's institution: |
Beijing YouAn Hospital Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学附属北京佑安医院 |
||
|
Affiliation of the Leader: |
Beijing YouAn Hospital Capital Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
京佑科伦字[2019]079号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医大学附属北京佑安医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Beijing You'an Hospital Affiliated to Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-07-29 00:00:00 |
||
|
伦理委员会联系人: |
孟莎 |
||
|
Contact Name of the ethic committee: |
Sha Meng |
||
|
伦理委员会联系地址: |
北京市丰台区右安门外西头条8号 |
||
|
Contact Address of the ethic committee: |
8 Xitoutiao, You'anmenwai, Fengtai District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 010 83997022 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
youanlunli@126.com |
|
研究实施负责(组长)单位: |
首都医科大学附属北京佑安医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing YouAn Hospital Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市丰台区右安门外西头条8号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
8 Xitoutiao, You'anmenwai, Fengtai District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国初级卫生保健基金会-佑安肝病艾滋病基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
China Primary Health Care Foundation-Youan Foundation of Liver Disease and AIDS |
||||||||||||||||||||||
|
Target disease: |
Mother-to-child blocking of hepatitis B |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
本研究旨在通过前瞻性研究,对不同喂养方式婴儿HBV感染风险的临床观察,进一步确认HBV-DNA高载量母乳喂养的安全性,使更多的HBV携带产妇能够安心地选择母乳喂养,缓解甚至消除HBV感染产妇焦虑、恐惧和内疚等不必要的心理压力,使她们的宝宝也能从母乳亲喂中充分获益,最大限度地促进该人群母婴健康。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to investigate the risk of the different feeding way in mothers with HBV infection to further confirm the safety of breastfeeding in mothers with HBV - DNA high loads. So as to make more HBV carriers can confidently choose breastfeeding, alleviate or even eliminate HBV infection in maternal unnecessary psychological pressure, such as anxiety, fear and guilt, make their babies also can full benefit that has come from the mother's milk, maximizing the maternal and child health crowd. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
符合《慢性乙型肝炎防治指南》慢性乙肝病毒感染诊断标准,选择 HBV-DNA≥1×106IU/ml免疫耐受孕妇,孕24-28周开始以宫内阻断为目的口服替比夫定或替诺福韦的产妇及其婴儿,孕周37W-42W,婴儿体重≥2500g,观察组持续母乳喂养(含混合喂养) 3-6个月。确保研究对象知情自愿选择参加本研究并具备随访条件。 |
||||||||||||||||||||||
|
Inclusion criteria |
In the chronic hepatitis b prevention guide "diagnostic criteria of chronic hepatitis b virus infection, HBV - DNA or 1 x 106 iu/ml immune tolerance for pregnant women, the house at 24 to 28 weeks began to block for than, or for the purpose of oral tenofovir maternal and infant, gestational age 37w - 42w, baby weight 2500 g, or observation group continued breastfeeding (including mixed feeding) 3 to 6 months. Ensure that the subjects voluntarily choose to participate in this study and are eligible for follow-up. |
||||||||||||||||||||||
|
排除标准: |
乙肝免疫耐受但未进行宫内阻断的孕妇、孕前即进行抗病毒治疗的慢性乙肝患者、孕期肝炎活动者,严重妊娠期合并症及并发症如妊娠合并心脏病、子痫前期重度、妊娠期糖尿病血糖控制不佳者、早产、FGR等。有严重内科合并症不适合母乳喂养者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Pregnant women with hepatitis b immune tolerance but without intrauterine blockade, chronic hepatitis b patients who received anti-viral treatment before pregnancy, hepatitis activists during pregnancy, severe gestational complications and complications, such as gestational heart disease, severe preeclampsia, poor blood glucose control of gestational diabetes mellitus, premature delivery, FGR, etc. People with severe medical complications are not suitable for breastfeeding. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-08-29 00:00:00至 To 2020-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2019-08-29 00:00:00 至 To 2020-05-29 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
non-randomized |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台, http://www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
upload to Resman, http://www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |